ArticleMedicine2026
Superselective transarterial embolization of intractable hematuria using Gelfoam particles: A retrospective single-center study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the effectiveness and clinical outcomes of superselective transarterial embolization (TAE) using Gelfoam particles for the management of intractable hematuria. Twenty patients (7 men and 13 women; mean age 70.65 years [range, 47-86 years]) with intractable hematuria who underwent superselective TAE between April 2014 and July 2021 were included in this retrospective study. Embolization of the vesical arteries was performed in all 20 patients using Gelfoam particles. Patients were divided into 2 groups based on the cause of hematuria: radiation cystitis and cancer bleeding. Retrospective evaluations of patient demographics, technical and clinical success rates, hematuria grade, serum hemoglobin (Hb) level (g/dL), complications, and mortality rate were performed. Hematuria was graded as follows: grade I (none); grade II (microscopic); grade III (macroscopic, without transfusion); grade IV (macroscopic, with intermittent transfusion); and grade V (macroscopic, with daily transfusion). The Wilcoxon signed-rank test was performed to compare the pre- and post-embolization hematuria grades and serum Hb levels within each group. The technical success rate was 100% (20/20 patients), and the overall clinical success rate was 85% (17/20 patients). The overall mean serum Hb level increased from 7.57 to 11.30 (P < .001), and the overall mean hematuria grade decreased from 4 to 2 (P < .001) after TAE. In the radiation cystitis group, the clinical success rate was 90% (10/11 patients), the mean serum Hb level increased from 7.8 to 12.2 (P = .004), and the mean hematuria grade decreased from 4 to 1.6 (P = .004). In the cancer bleeding group, the clinical success rate was 77% (7/9 patients), the mean serum Hb level increased from 7.3 to 10.2 (P = .021), and the mean hematuria grade decreased from 4 to 2.4 (P = .017). Minor complications were noted in 8/20 (40%) cases, notably post-embolization syndrome, managed conservatively. No major complications occurred in either group. Eleven deaths occurred during the mean follow-up period of 9.6 ± 31 months, and none of the deaths were procedure-related. Superselective TAE with Gelfoam particles is a feasible, effective, and safe treatment for intractable hematuria, both in patients with radiation cystitis and cancer bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.